NLS Pharmaceutics Regains Compliance with Nasdaq Stockholders' Equity Requirement
NLS Pharmaceutics Ltd. (NASDAQ: NLSP, NLSPW) announced on January 25, 2023, that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies to maintain a minimum stockholders' equity of $2,500,000. This follows a notification letter from the Nasdaq Hearings Panel confirming the company's adherence to the rule. NLS was first notified of its non-compliance on April 1, 2022, but through an appeal process, it received approval to continue its Nasdaq listing. The Panel's recent confirmation resolves all outstanding compliance issues.
- NLS Pharmaceutics regained compliance with Nasdaq Listing Rule 5550(b)(1).
- The company resolved both outstanding Nasdaq compliance issues successfully.
- None.
ZURICH, SWITZERLAND / ACCESSWIRE / January 25, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it received a notification letter from the Hearings Panel (the "Panel") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders' equity of at least
As previously announced, on April 1, 2022, NLS was first notified by Nasdaq of its failure to comply with Nasdaq Listing Rule 5550(b)(1). As reported on November 14, 2022, following an appeal by NLS, the Panel granted the Company's request to continue its listing on Nasdaq and further requested that the Company demonstrate compliance with Listing Rule 5550(b)(1) no later than February 28, 2023.
On January 24, 2023, the Panel confirmed the Company's compliance with the previously communicated conditions and determined that the Company regained compliance with Listing Rule 5550(b)(1). Accordingly, the Panel has determined to continue the listing of the Company's securities on Nasdaq and considers this matter closed.
About NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd. (Nasdaq: NLSP) is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system, or CNS, disorders, who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit www.nlspharma.com.
For additional information:
Marianne Lambertson (investors & media)
NLS Pharmaceutics Ltd.
+1 239.682.8500
ml@nls-pharma.com
###
SOURCE: NLS Pharmaceutics AG
View source version on accesswire.com:
https://www.accesswire.com/736677/NLS-Pharmaceutics-Regains-Compliance-with-Nasdaq-Stockholders-Equity-Requirement
FAQ
What was the reason for NLS Pharmaceutics receiving a notification from Nasdaq?
What does regaining compliance with Nasdaq Listing Rule 5550(b)(1) mean for NLS Pharmaceutics?
When did NLS Pharmaceutics first learn about its compliance issue with Nasdaq?
What actions did NLS Pharmaceutics take to regain compliance?
